Results 151 to 160 of about 2,242,189 (260)

p300 Degradation by the p53‐SIAH1 Axis Relieves TBK1 Acetylation to Enhance Innate Antiviral Immunity

Advanced Science, Volume 13, Issue 50, 7 September 2026.
This study identifies p300 as the acetyltransferase that acetylates TBK1 and inhibits its phosphorylation. Activation of the p53‐SIAH1 axis by immune response downregulates p300 expression to sustain innate antiviral immunity. Conditional p300 knockout in alveolar epithelial cells in vivo promotes antiviral responses and suppresses virus replication ...
Huidi Yu, Zhihao Zhan, Xiaoxiang Pan, Xinyue Zhang, Penggang Liu, Jing Sun, Xiulong Xu   +6 more
wiley   +1 more source

Single-Cell Profiling Identifies the SPDEF/GAS5 Axis as a Potential Driver of Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer. [PDF]

Cureus
Jin W, Chen C, Zhou Y, Wang J, Hou R, Shi WJ.   +5 more
europepmc   +1 more source

The role of mitochondrial/metabolic axis in development of tamoxifen resistance in breast cancer. [PDF]

Hum Cell, 2023
Azzam HN, El-Derany MO, Wahdan SA, Faheim RM, Helal GK, El-Demerdash E.   +5 more
europepmc   +1 more source

Reactive Oxygen Species in Breast Cancer: From Redox Dysregulation to ROS‐Responsive Therapeutics

Cell Biochemistry and Function, Volume 44, Issue 9, September 2026.
ABSTRACT Breast cancer is the most frequently diagnosed malignancy among women worldwide, with 2.3 million new cases and approximately 670,000 deaths reported in 2022 alone. Despite advances in therapy, metastasis and acquired drug resistance remain major clinical challenges.
Marija Nikolovska, Radoslav Stojchevski, Aleksandar Eftimov, Mitko Mladenov, Dimiter Avtanski, Nikola Hadzi‐Petrushev   +5 more
wiley   +1 more source

ASH2L induces tamoxifen resistance via H3K4me3 dependent ITGA6/ERK signaling in ER-positive breast cancer. [PDF]

Br J Cancer
Kye YH, Moon SJ, Cha HR, Kim TH, Eom JY, Myung JK, Kong G.   +6 more
europepmc   +1 more source

Inhibition of Increased Invasiveness of Breast Cancer Cells With Acquired Tamoxifen Resistance by Suppression of CYR61. [PDF]

Cancer Genomics Proteomics, 2023
Bauerschmitz G, Hüchel S, Gallwas J, Gründker C.   +3 more
europepmc   +1 more source

An In Vitro and In Vivo Assessment of the Anti‐Breast Cancer Activity of Erythrina excelsa Baker (Fabaceae) Bark Extracts

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Breast cancer remains a topic of interest due to its high mortality rate among Cameroonian women. The barks of Erythrina excelsa are traditionally used for medicinal purposes in the management of various conditions including cancer.
Jonas Walantini, Marius Trésor Kemegne Sipping, Merline Nguedia Ymele, Roland Nhouma Rebe, Joël Abel Gbaweng Yaya, Derek Tantoh Ndinteh, Dieudonné Njamen, Stéphane Zingue   +7 more
wiley   +1 more source

STAMBP Accelerates Progression and Tamoxifen Resistance of Breast Cancer Through Deubiquitinating ERα. [PDF]

Biomolecules
Wang Z, Gu L, Yang M, Zhou Y, Qin X, Xiong C.   +5 more
europepmc   +1 more source

RelB-activated GPX4 inhibits ferroptosis and confers tamoxifen resistance in breast cancer. [PDF]

Redox Biol, 2023
Xu Z, Wang X, Sun W, Xu F, Kou H, Hu W, Zhang Y, Jiang Q, Tang J, Xu Y.   +9 more
europepmc   +1 more source

The Roles of EETs in Neurological Disorders

CNS Neuroscience &Therapeutics, Volume 32, Issue 9, September 2026.
Epoxyeicosatrienoic acids (EETs), derived from arachidonic acid (ARA) via cytochrome P450 (CYP450) enzymes, are produced in nearly all human tissues and exert a wide range of beneficial effects. This review summarizes the roles and potential mechanisms of EETs in neurological disorders, with a focus on cerebrovascular diseases, epilepsy, Parkinson's ...
Rong Tang, Mengya Li, Banglian Hu, Guoqiang Fei, Honghua Zheng, Xin Wang, Jing Ding   +6 more
wiley   +1 more source